Opicapone: A short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects

British Journal of Clinical Pharmacology

Volumn 76, Issue 5, 2013, Pages 763-775

  Rocha, José Francisco ^a   Almeida, Luis ^b   Falcão, Amílcar ^c   Palma, P Nuno ^a   Loureiro, Ana I ^a   Pinto, Roberto ^a,d   Bonifácio, Maria João ^a   Wright, Lyndon C ^a   Nunes, Teresa ^a   Soares da Silva, Patrício ^a,d  

^a Department of Research and Development ^*  (Portugal)

^b UNIVERSITY OF AVEIRO   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d University of Porto   (Portugal)

Author keywords

Catechol O methyltransferase; COMT inhibition; Opicapone; Pharmacodynamics; Pharmacokinetics

Indexed keywords

OPICAPONE; PLACEBO;

ADULT; ARTICLE; BILE; BLOOD SAMPLING; CLINICAL RESEARCH; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; FOLLOW UP; HEMIPARESIS; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; MUSCLE SPASM; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; URINALYSIS; URINE; VOMITING;

CATECHOL-O-METHYLTRANSFERASE; COMT INHIBITION; OPICAPONE; PHARMACODYNAMICS; PHARMACOKINETICS;

ADULT; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; ERYTHROCYTES; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; OXADIAZOLES; YOUNG ADULT;

EID: 84886928771     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12081     Document Type: Article

References (29)

1. Morgan JC, Sethi KD. Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs 2006; 11: 403-417.
2. Schapira AH, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinson's disease. Eur J Neurol 2009; 16: 982-989.
3. Dingemanse J. Issues important for rational COMT inhibition. Neurology 2000; 55: (11 Suppl. 4): S24-27. discussion S28-32.
4. Palma PN, Bonifácio MJ, Almeida L, Soares-Da-Silva P. Restoring dopamine levels. In: Protein Misfolding in Neurodegenerative Diseases: Mechanisms and Therapeutic Strategies, eds Simth HJ, Simons C, Sewell RDE. Boca Raton, FL: CRC Press, 2007; 415-445.
5. Gomes P, Soares-da-Silva P. Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells. Neuropharmacology 1999; 38: 1371-1380.
6. Gervas JJ, Muradas V, Bazan E, Aguado EG, de Yebenes JG. Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 1983; 33: 278-282.
7. Nutt JG, Woodward WR, Gancher ST, Merrick D. 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1987; 21: 584-588.
8. Wade LA, Katzman R. 3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sci 1975; 17: 131-136.
9. Olanow CW, Stocchi F. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology 2004; 62: (1 Suppl. 1): S72-81.
10. Bonifácio MJ, Palma PN, Almeida L, Soares-da-Silva P. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev 2007; 13: 352-379.
11. Lang AE, Lees A. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17: (Suppl. 4): S45-51.
12. Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology 2004; 62: (1 Suppl. 1): S39-46.
13. Kiss LE, Ferreira HS, Torrao L, Bonifacio MJ, Palma PN, Soares-da-Silva P, Learmonth DA. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem 2010; 53: 3396-3411.
14. Palma PN, Bonifácio MJ, Loureiro AI, Soares-da-Silva P. Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations. J Comput Chem 2012; 33: 970-986.
15. Bonifácio MJ, Torrão L, Loureiro AI, Wright LC, Soares-da-Silva P. Opicapone: characterization of a novel peripheral long-acting catechol-O-methyltransferase inhibitior. Parkinsonism Relat Disord 2012; 18: (S2): S125.
16. Bonifácio MJ, Sutcliffe JS, Torrão L, Wright LC, Soares-da-Silva P. Brain and peripheral levodopa pharmacokinetics in the Cynomolgus monkey following administration of opicapone, a novel catechol-O-methyltransferase inhibitor. Parkinsonism Relat Disord 2012; 18: (S2): S125.
17. Nunes T, Rocha JF, Pinto R, Machado R, Wright LC, Falcao A, Almeida L, Soares-da-Silva P. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel COMT inhibitor, during first administration to healthy male subjects. Parkinsonism Relat Disord 2012; 18: (S2): S126.
18. Lees A, Costa R, Oliveira C, Lopes N, Nunes T, Soares-da-Silva P. The design of a double-blind, placebo-controlled, multi-national phase-III trial in patients with Parkinson's disease and end-of-dose motor fluctuations: opicapone superiority vs. placebo. Mov Disord 2012; 27: (Suppl. 1): S127.
19. Ferreira JJ, Rocha JF, Santos A, Nunes T, Soares-da-Silva P. The design of a double-blind, placebo- and active-controlled, multi-national phase-III trial in patients with Parkinson's disease and end-of-dose motor fluctuations: opicapone superiority vs. placebo and non-inferiority vs. entacapone. Mov Disord 2012; 27: (Suppl. 1): S118.
20. FDA/CDER. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2000.
21. Vieira-Coelho MA, Soares-da-Silva P. Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Br J Pharmacol 1996; 117: 516-520.
22. Vieira-Coelho MA, Soares-da-Silva P. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Brain Res 1999; 821: 69-78.
23. Ferreira JJ, Almeida L, Cunha L, Ticmeanu M, Rosa MM, Januário C, Mitu CE, Coelho M, Correia-Guedes L, Morgadinho A, Nunes T, Wright LC, Falcão A, Sampaio C, Soares-da-Silva P. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. Clin Neuropharmacol 2008; 31: 2-18.
24. Copeland RA, Pompliano D. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006; 5: 1-10.
25. Tummino PJ, Copeland RA. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 2008; 47: 5481-5492.
26. Vauquelin G, Van Liefde I. Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol Sci 2006; 27: 356-359.
27. Vidgren J, Svensson LA, Liljas A. Crystal structure of catechol O-methyltransferase. Nature 1994; 368: 354-358.
28. Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zürcher G, Da Prada M, van Brummelen P. Integrated pharmacokinetics and pharmacodynamics of the novel catechol- O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995; 57: 508-517.
29. Keranen T, Gordin A, Karlsson M, Korpela K, Pentikainen PJ, Rita H, Schultz E, Seppala L, Wikberg T. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 1994; 46: 151-157.